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In the ubiquitin-proteasome system (UPS), E2
enzymes mediate the conjugation of ubiquitin to
substrates and thereby control protein stability and
interactions. The E2 enzyme hCdc34 catalyzes the
ubiquitination of hundreds of proteins in conjunction
with thecullin-RING (CRL)superfamilyofE3enzymes.
We identified a small molecule termed CC0651 that
selectively inhibits hCdc34. Structure determination
revealed that CC0651 inserts into a cryptic binding
pocket on hCdc34 distant from the catalytic site,
causing subtle but wholesale displacement of E2
secondary structural elements. CC0651 analogs in-
hibited proliferation of human cancer cell lines and
caused accumulation of the SCFSkp2 substrate
p27Kip1. CC0651 does not affect hCdc34 interactions
withE1orE3enzymesor the formationof theubiquitin
thioester but instead interferes with the discharge of
ubiquitin to acceptor lysine residues. E2 enzymes
are thus susceptible to noncatalytic site inhibition
and may represent a viable class of drug target in
the UPS.
INTRODUCTION
The ubiquitin-proteasome system (UPS) controls the stability,
interactions, and localization of many thousands of proteins
across virtually all cellular processes. Ubiquitin conjugation to
substrate lysine residues is catalyzed by a conserved enzymatic
cascade: an E1 enzyme activates ubiquitin as a thioester in an
ATP-dependent manner and transfers the activated ubiquitin to
the catalytic cysteine residue of an E2, which then interacts
with an E3 enzyme to conjugate ubiquitin as an isopeptidebond onto the substrate (Nalepa et al., 2006). E3 enzymes,
also referred to as ubiquitin ligases, confer substrate specificity
via specific protein interaction domains and fall into two broad
classes: the HECT domain class forms a catalytic ubiquitin thio-
ester intermediate, whereas the RING domain class juxtaposes
the charged E2 next to the substrate (Pickart, 2001). The human
genome encodes two E1 enzymes, at least 38 E2 enzymes, and
more than 600 distinct E3 enzymes, each of which has the poten-
tial to recognize multiple substrates (Li et al., 2008).
The largest family of E3 enzymes, the cullin-RING ligases
(CRLs), were first discovered as the multisubunit Skp1-Cdc53/
Cullin-F box protein (SCF) ubiquitin ligases. SCF complexes
contain the core subunits Skp1, Cdc53/Cul1, and Rbx1/Roc1/
Hrt1 and a cohort of adaptor subunits called F box proteins
that recruit specific substrates to the core complex, often in
a phosphorylation-dependent manner (Bai et al., 1996; Feldman
et al., 1997; Patton et al., 1998; Petroski and Deshaies, 2005;
Skowyra et al., 1997;Willems et al., 1996). As for all RINGdomain
E3 enzymes, SCF complexes capture substrates for E2-medi-
ated ubiquitination but do not possess catalytic activity per se
(Petroski and Deshaies, 2005). SCF-like complexes built on
a similar adaptor-cullin-RING architecture include the anaphase
promoting complex/cyclosome and the Cul2-, Cul3-, Cul4A-,
Cul5-, and Cul6-based ubiquitin ligases. The CRL class thus
has the capacity to target many hundreds, if not thousands, of
proteins for degradation (Petroski and Deshaies, 2005; Yen
and Elledge, 2008). A crucial requisite for CRL activity is covalent
modification of the cullin subunit by a ubiquitin-like modifier
called Nedd8 (Petroski and Deshaies, 2005). Nedd8modification
dramatically increases the conformational flexibility of the Rbx1
subunit to allow the docked E2 to efficiently access substrate
lysine residues (Duda et al., 2008).
E2 enzyme properties govern both the type of ubiquitin linkage
and the extent of ubiquitin modification (Wenzel et al., 2010;
Ye and Rape, 2009). Monoubiquitination typically alters pro-
tein interactions in vesicle trafficking, DNA repair, and otherCell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc. 1075
processes, whereas polyubiquitination usually leads to substrate
recognition and degradation by the 26S proteasome (Ravid and
Hochstrasser, 2008). Different E2 enzymes can build polymers
with different ubiquitin linkages, which can also lead to different
fates. Multiple mechanisms—including E3 multimerization and
conformational changes, ubiquitin placement and chain
assembly on the E2, and E2-specific initiation versus elongation
steps—all serve to coordinate E2 loading and unloading cycles
with substrate-E3 interactions (Ye and Rape, 2009). Notably,
the primary E2 for the CRL class, Cdc34, acts in a highly proces-
sive fashion due to the rapid exchange of its unique acidic
C-terminal tail with the cullin subunit (Kleiger et al., 2009; Pierce
et al., 2009).
As the UPS is frequently perturbed in cancer, neurological,
and immunological disorders and infectious disease, the modu-
lation of UPS enzymatic activities is of intense therapeutic
interest (Cohen and Tcherpakov, 2010; Nalepa et al., 2006). In
particular, the F box proteins Skp2 and b-TrCP are often overex-
pressed in primary cancers, whereas Fbw7 is a frequent mutated
tumor suppressor (Frescas and Pagano, 2008; Welcker and
Clurman, 2008). Phosphorylation of the cyclin-dependent kinase
(CDK) inhibitor p27Kip1 by cyclin E-Cdk2 drives its recognition
and ubiquitination by SCFSkp2, thereby enabling cell-cycle
progression through G1 phase (Frescas and Pagano, 2008). As
the SKP2 locus is often amplified and overexpressed in human
cancer, SCFSkp2 is a candidate target for therapeutic intervention
(Nalepa et al., 2006). HumanCRLs have been subjected to small-
molecule screens to identify inhibitors of different catalytic and
substrate recognition steps (Aghajan et al., 2010; Chen et al.,
2008; Orlicky et al., 2010; Soucy et al., 2009). Here, we report
a small-molecule screen for inhibitors of SCFSkp2-dependent
ubiquitination of p27Kip1 and identify a novel allosteric inhibitor
of the human Cdc34 enzyme.
RESULTS
A Small-Molecule Screen against SCFSkp2 Identifies
a hCdc34 Inhibitor
To screen for small-molecule inhibitors of all key steps in an SCF-
catalyzed ubiquitination reaction, we developed a HTP-compat-
ible assay based on ubiquitination of the human CDK inhibitor
p27Kip1 by the SCFSkp2 E3 complex (Chen et al., 2008). This
recombinant assay system contained biotinylated-ubiquitin,
the E1 enzyme Uba1, the E2 enzyme hCdc34, the SCFSkp2
complex, Cks1, and p27Kip1 that was phosphorylated by cyclin
E-Cdk2. Ubiquitination of p27Kip1 was assessed by capture
onto an anti-p27Kip1 antibody affinity surface and quantitative
detection with a europium-streptavidin conjugate. In an exten-
sive small-molecule campaign, we identified a compound desig-
nated CC0651 that potently (IC50 = 1.72 mM) inhibited the ubiq-
uitination of p27Kip1, as confirmed by dose-response analysis
(Figure 1A). CC0651 corresponds to (2R,3S,4S)-5-(30,50-dichlor-
obiphenyl-4-yl)-2,3-dihydroxy-4-(2-methoxyacetamido) penta-
noic acid and has a molecular mass of 442.3 g/mol (Figure 1B).
The calculated Log P and Log D values for CC0651 were 2.46
and 0.985, with an aqueous solubility of 1 mg/ml at pH 7.4.
CC0651 contains three chiral centers and was resynthesized
for use in all subsequent assays in enantiomerically pure form.1076 Cell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc.To narrow down the potential target(s) for CC0651 in the multi-
component SCFSkp2 reaction, we tested its activity against other
E3 enzymes and substrates. CC0651 inhibited the activity of
SCFb-TrCP1 toward a phospho-IkBa peptide and of SCFFbw7
toward phospho-cyclin E (Figure 1C), suggesting that CC0651
was not selective for different SCF complexes. CC0651 had no
effect on activity of the human HECT domain enzyme SMURF2,
the Shigella IpaH enzyme SspH1, or the human RING domain
enzyme Rnf168 (Figure S1A–S1C available online). Because
ubiquitin and E1 enzyme were common to all five of the in vitro
reactions tested, we excluded both of these components as
targets of CC0651. The remaining possible targets for CC0651
were thus the E2 enzyme hCdc34 and the core SCF subunits
Skp1, Cul1, and Rbx1.
We used an in vitro reaction reconstituted from budding yeast
Cdc34 and SCFCdc4 to delineate CC0651 mechanism of action
(Orlicky et al., 2003). CC0651 had no effect on ubiquitination of
the yeast CDK inhibitor Sic1 in the yeast Cdc34-SCFCdc4 reac-
tion (Figure 1D). However, substitution of yeast Cdc34 with
hCdc34 in this reaction caused CC0651 to robustly inhibit Sic1
ubiquitination (Figure 1D). Thermal denaturation assays sug-
gested that CC0651 specifically bound to hCdc34, but not to
other control proteins (Figure S2A–S2F). These biochemical
and biophysical data strongly suggested that the target of
CC0651 is hCdc34.
Structural Analysis of hCdc34 Alone and in Complex
with CC0651
To investigate themechanismwherebyCC0651 inhibits hCdc34,
we determined the structure of hCdc34 alone and in complex
with CC0651. Although many E2 enzyme structures are known
(Burroughs et al., 2008; Wenzel et al., 2010; Ye and Rape,
2009), the structure of Cdc34 has not been solved previously.
hCdc34 possesses a conserved acidic C-terminal extension of
54 residues that is critical for its efficient interaction with Cul1
but is not required for catalytic activity per se (Kleiger et al.,
2009). A C-terminal deletion construct that lacks the acidic tail,
denoted hCdc34D184 (Figure S3), yielded crystals suitable for
structure determination by molecular replacement using
UbcH7 coordinates (PDB 1FBV) as a search model. Data collec-
tion and refinement statistics for the apo- and inhibitor-bound
hCdc34D184 structures, resolved at 2.4 A˚ and 2.3 A˚ resolution,
respectively, are summarized in Table S1.
The structure of hCdc34D184 consists of a four-stranded anti-
parallel b sheet, denoted strands b1 to b4, flanked by four
a helices, denoted helices a1 to a4 (Figure 2A). This structure
is similar to that of all other E2 structures solved to date (Bur-
roughs et al., 2008). The two long connector segments that link
strand b4 with helix a2 and helix a2 with helix a3 comprise the
active site region of the E2 enzyme. The catalytic cysteine
residue Cys93 lies within the b4-a2 connector and immediately
precedes the structurally conserved 310 helix. The sequence
that links the 310 helix to helix a2 of hCdc34 is 13 residues longer
than in most other E2s; 15 residues of this linker sequence are
disordered in the hCdc34D184 structure. We note that, in the
apo hCdc34D184 structure, the catalytic cysteine forms adisulfide
bridge with a symmetry-related molecule in the crystal. This arti-
ficial crosslink appears to distort the orientation of the 310 helix
BOH
OH
O
OH NH
O
O
Cl Cl
D
1
2
3
4
5
6
1
2
3
4
5
6
methoxy
moiety
acetamido
moiety
pentanoic 
acid moiety
1 2
3
4 5
1
2
[CC0651] μM
dichlorobiphenyl
moiety 
A
p2
7 
ub
iq
ui
tin
at
io
n 
(%
)
pSic1
pSic1-(Ub)n
CC0651(μM)
yCdc34hCdc34
-E
2
0 1 3 10
 
33
 
10
0 
0 1 3 10
 
33
 
10
0 
SCFβTrCP SCFSkp2 SCFFbw7
in
pu
t
0 1 3 10 33 10
0
in
pu
t
0 1 3 10 33 10
0
0 1 3 10 33 10
0
CC0651
0.1 1 100100.01
0
30
60
90
120
IC50=1.72 +/- 0.36μM
CC0651(μM)
free substrate
substrate-(Ub)n
C
Figure 1. CC0651 Is a Small-Molecule Inhibitor of hCdc34
(A) Inhibition of phospho-p27Kip1ubiquitination by SCFSkp2 monitored by incorporation of biotinylated ubiquitin. Ubiquitination measurements represent the
mean ± STDEV from five replicates.
(B) Structure of CC0651.
(C) Inhibition profiles of CC0651 against different SCF complexes. Biotinylated phospho-IkBa peptide, p27Kip1, or cyclin E substrates were incubated in reactions
with recombinant SCFb-TrCP, SCFSkp2, or SCFFbw7and the indicated concentrations of CC0651 and were visualized by immunoblot.
(D) Inhibition profile of CC0651 against phospho-Sic1 ubiquitination catalyzed by SCFCdc4 and hCdc34 or yeast Cdc34, as visualized by anti-Sic1 immunoblot.
See Figure S1 and Figure S2 for associated data.relative to other E2 structures. For this reason, in subsequent
analyses, we used the structures of UbcH5b or Ubc9 as alternate
reference points for active apo-E2 structures (Ozkan et al., 2005;
Yunus and Lima, 2006).
The structure of the CC0651-hCdc34D184 complex was solved
by molecular replacement using the apo-hCdc34D184 coordi-
nates as a search model. This analysis revealed unambiguouselectron density for CC0651 at a site 19 A˚ distal from the active
site residue Cys93 (Figure 2B and Figure S4A). The asymmetric
unit of this crystal form contained four molecules of hCdc34D184,
with each bound to similarly oriented CC0651 molecules
(Figure S4B). Two of the hCdc34D184 molecules (chains C and
D) again formed a disulfide bridge linked through the active
site cysteine. As this covalent linkage is unlikely to reflectCell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc. 1077
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a biologically relevant conformation, we focused our analysis on
the two noncovalently linked hCdc34D184 molecules (chains A
and B).
CC0651 bound to a pocket formed by the a1-b1 linker, the
C-terminal end of helix a2, the b2-b3 linker, the C-terminal end
of helix a3, and the a3-a4 linker (Figures 2B and 2C). The
354 A˚2 contact surface between CC0651 and hCdc34D184 was
dominated by hydrophobic interactions. The biphenyl ring
system of CC0651 embedded within a hydrophobic pocket lined
by Phe28, Ile45, Pro48, Tyr53, Phe58, Phe77, Met81, Ile128,
Leu131, and Ile165. The aliphatic portion of CC0651 engaged
a mixed polar and hydrophobic environment created by Asn50,
Tyr52, Pro134, Tyr148, Trp151, Tyr161, and Thr162. Despite
the potential for hydrogen bond interactions, only one such inter-
action was observed, namely between the backbone amide
group of Tyr52 with the acetamido carbonyl group of CC0651.
Consistent with this dearth of polar interactions, the carboxylic
acid group of CC0651 sampled alternate binding conformations
in the four copies of hCdc34D184 within the crystal asymmetric
unit (Figure S4B).
Mutational Analysis of the CC0651 Binding Pocket
Sequence comparisons revealed that many of the residues that
line the inhibitor binding pocket are unique to hCdc34 and its
close homolog Ube2R2 (Figure S3). These differences may
account for the observed inhibitory properties of CC0651 toward
hCdc34, but not UbcH5, UbcH7, or Ubc13/Uev1a. To validate
the CC0651 binding mode observed in the crystal structure
and to probe the determinants of inhibitor selectivity, we
mutated critical but nonconserved binding pocket residues
and examined the effect of these mutations in the hCdc34-yeast
SCFCdc4 assay. Tyr52 occupies a highly variable position in
hCdc34 yet appeared vital for organizing the b2-b3 loop that
forms the only strong hydrogen bond with CC0651. This position
is occupied by Tyr or Phe only in the two human E2 enzymes
Ube2F and Ube2M/Ubc12, respectively. Ile128 and Asn132
both lie in helix a2 and interact with the biphenyl system of
CC0651; these positions are also highly variable in different E2
enzymes. As predicted from the CC0651-hCdc34 structure,
mutation of each of the contact residues attenuated the inhibi-
tory effect of CC0651 on hCdc34 without compromising enzy-
matic activity toward Sic1 (Figure 2D). As no other human E2s
possess each of the Tyr, Ile, and Asp contact residues,
CC0651 is likely to selectively inhibit hCdc34. Indeed, Ube2R2
lacks only the Tyr contact residue compared to hCdc34 and
yet is fully resistant to CC0651 in the surrogate Sic1 ubiquitina-
tion assay (Figure 2E).Figure 2. Structure of hCdc34 Alone and in Complex with CC0651
(A) hCdc34 structure superimposed on the E2 domain of UbcH5b (PDB 2ESK) (O
(B) hCdc34 structure in complex with CC0651.
(C) Stereoview of CC0651 contact residues in hCdc34. CC0651 is in yellow, conta
hCdc34 is shown by a dashed line.
(D) Effect of binding pocket mutations on hCdc34 inhibition by CC0651. Phospho-
or mutant versions of hCdc34 in the absence or presence of CC0651 and was v
(E) Ube2R2 is resistant to inhibition by CC0651. Reactions were performed as
concentrations of CC0651.
See Figure S3 and Figure S4 for associated data.Structure-Activity Relationships of CC0651 Analogs
Wesynthesized 12 analogs ofCC0651 and compared their ability
to inhibit hCdc34-dependent Sic1 ubiquitination in vitro (Figures
3A and 3B) and also the activity of SCFSkp2, SCFbTrCP, and
SCFFbw7 (see Figure S5 and Figure S6 for dose-response
profiles). Increasing the separation of the twophenyl ring systems
by insertion of an intervening amino group (CC9833) resulted in
the complete loss of inhibitory activity. Similarly, elimination or
substitution of the entire polar pentanoic acid-acetoamido-me-
thoxy system (CC9430, CC9504, CC9535, and CC9566) resulted
in a complete loss of inhibitory function. Thus, both the hydro-
phobic and polar elements of CC0651 are essential for hCdc34
inhibition.
We then generated more subtle substitutions in the polar half
of CC0651. Analogs that substituted or blocked the carboxylate
moiety of the pentanoic acid group with a hydroxyl moiety
(CC9933), an aliphatic amine (CC9807), a five-chain ether moiety
(CC7094), or methoxy ester linkage (CC8993) retained inhibitory
activity with descending potency. Activity was weakly affected
by modification of the two hydroxyl groups by reduction
(CC0040) or by cyclization (CC9653); the reduced analog
simplifies the synthetic route by eliminating two of three chiral
centers in CC0651. Finally, substitution of the methoxy group
with a benzyl group in the reduced analog (CC9652) demon-
strated that the ether groupwas not essential for activity. Though
we did not target the acetamido carbonyl group of CC0651 for
modification, based on the polar region analogs, we predict
that this moiety is important for function. None of the CC0651
analogs exhibited significant activity against Ube2R2, demon-
strating that E2 selectivity was retained across the series (Fig-
ure S5). These in vitro SAR results delineate the key features of
CC0651 and provide a basis for further compound optimization.
Activity of CC0651 Analogs In Vivo
We then determined whether CC0651 or any of its analogs had
biological activity in human cells. Antisense suppression of
hCdc34 in human diploid fibroblasts is known to elevate
p27Kip1 levels (Butz et al., 2005), and consistently we found
that shRNA-mediated hCdc34 silencing caused p27Kip1 accu-
mulation and inhibition of cell proliferation in both the PC-3 pros-
tate and HCT 116 colorectal cancer cell lines, without affecting
p27Kip1 mRNA levels (Figures S7A–S7C). Specific knockdown
of either hCdc34 or Ube2R2 caused equivalent effects on
p27Kip1 and proliferation, suggesting that the two E2 isoforms
function in a partially nonredundant manner. We then tested
CC0651 and its analogs for effects on PC-3 cells. The CC7094
analog, which has modest activity in vitro, and an ester analogzkan et al., 2005).
ct residues in hCdc34 are in blue, and a hydrogen bond between CC0651 and
Sic1 was incubated in reactions with recombinant SCFCdc4 and either wild-type
isualized by anti-Sic1 immunoblot.
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Figure 3. Structure-Activity Relationship Analysis of CC0651
(A) Structures of CC0651 and its analogs. Circles highlight differences between the analog and the parent compound.
(B) Effect of CC0651 and the indicated analogs (all 200 mM) on ubiquitination of Sic1 by hCdc34 and yeast SCFCdc4. Asterisk denotes analogs that retain
biochemical activity.
See Figure S5 and Figure S6 for dose-response profiles of all analogs, including the methyl ester derivative CC8993.of CC0651 (CC8993) inhibited cell proliferation with an IC50
of 20 mM (Figure 4A) and caused a progressive increase in
p27Kip1 levels (Figure 4B), again without affecting p27Kip1
mRNA (Figure S7D). Consistently, upon exit from quiescence
in the presence of inhibitor analogs, p27Kip1 and cyclin E levels
were also elevated (Figure 4C and Figures S7E and S7F). In
comparison, the potent Nedd8-activating enzyme inhibitor
MLN4924, which abrogates all SCF and CRL ubiquitin ligase
activity (Soucy et al., 2009), caused more pronounced p27Kip1
and cyclin E accumulation in this assay. The moderate accumu-
lation of p27Kip1 in these assays probably reflects the limited1080 Cell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc.bioavailability of the first-generation CC0651 derivatives, as
well as parallel p27Kip1 degradation pathways in vivo (Kamura
et al., 2004). To further validate that the effects of the inhibitor
were mediated through hCdc34, we added the ester analog
CC8993 to PC-3 cells that had been infected with an shRNA
against hCdc34. The prior reduction of hCdc34 expression
largely abrogated the effect of the inhibitor on cell proliferation
(Figure 4D). In a parallel assay for target specificity, we observed
that treatment of cells with the ester analog caused accumula-
tion of a covalent hCdc34-ubiquitin conjugate (Figure 4E), which
is a known byproduct of Cdc34-dependent catalysis (Scaglione
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(A) PC-3 cultures were treated with CC7094 or CC8993 for 5 days and proliferation assessed by MTT assay. Values correspond to mean ± SEM of quadruplicate
determinations.
(B) PC-3 cultures were treated with CC7094 or DMSO control for the indicated times and p27Kip1abundance determined by immunoblot.
(C) G0/G1-synchronized PC-3 cultures were treated with DMSO or CC0651, CC7094, or CC8993 (all at 30 mM) or MLN4924 (4 mM) for 16 hr, followed by detection
of p27Kip1 and cyclin E by immunoblot.
(D) PC-3 cultures were infected with lentiviruses encoding control nontarget (NT) or hCdc34-specific shRNA 24 hr prior to treatment with CC8993 for 4 days and
proliferation assessed by MTT assay. Values correspond to mean ± SEM of six determinations.
(E) Posttranslational modification of hCdc34 in G0/G1-synchronized PC-3 or HCT 116 cultures treated with DMSO, CC7094 (30 mM) or CC8993 (30 mM), or
MLN4924 (4 mM) and analyzed by anti-Cdc34 immunoblot under reducing conditions.
See Figure S7 for associated data.et al., 2007). The appearance of the conjugate was not merely
a consequence of SCF pathway inhibition because it did not
arise upon MLN4924 treatment, and consistently, CC0651
caused production of the hCdc34-ubiquitin conjugate during
in vitro reactions (see below). Collectively, these data suggest
that CC0651 and some of its analogs are able to specifically
interdict hCdc34 function in vivo, with concomitant effects on
p27Kip1 accumulation and cell proliferation.Induction of the CC0651 Binding Pocket Causes Large-
Scale Structural Rearrangements
Comparison of the apo- and CC0651-bound structures of
hCdc34, which have an RMSD of 0.94 A˚ over 142 residues, re-
vealed that the CC0651-binding pocket is only partially pre-
formed in the absence of the inhibitor (Figure 5A). We thus
considered the possibility that long-range structural distortions
resulting from induction of the binding pocket might explainCell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc. 1081
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Figure 5. Influence of CC0651 Interactions on hCdc34 Structure
(A) Surface representation (left) of the CC0651 binding pocket in the CC0651-hCdc34 structure (cyan) and in the apo-hCdc34 structure (pink). Ribbons repre-
sentation of (right) the CC0651-hCdc34 complex superimposed on apo-hCdc34. Arrows indicate rigid body movements of secondary structure elements
induced by CC0651 binding.
(B) Distortion of the active site of hCdc34 induced by CC0651. Structures were superimposed for apo- hCdc34, hCdc34 in complex with CC0651, and Ubc9 in
complex with an acceptor substrate RanGap1 (PDB 2GRN) (Yunus and Lima, 2006).
(C)Ribbons representationof thehCdc34-CC0651structuresuperimposedon theE2domainofUbc1engagedwithdonorubiquitin (PDB1FXT) (Hamiltonetal., 2001).
See Figure S8 and Figure S11 for associated data.the inhibitory effects of CC0651. Preformed cavities that accom-
modate themoieties at each end of CC0651, namely for the chlo-
rine atom of the first phenyl ring system and the methoxyl
aliphatic chain, are apparent in the apo-hCdc34 structure (Fig-
ure 5A). In contrast, the central region of the binding pocket1082 Cell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc.that accommodates the bulky biphenyl ring system is completely
occluded in the absence of CC0651. Induction of the binding
pocket arises from the outward displacement of helix a2 by
2.1 A˚ and of the b2-b3-connecting segment by 1.7 A˚ (Figure 5A).
These motions create a cavity that exposes the hydrophobic
core of hCdc34 and causes compensatory inward movement of
helix a1, the a1-b1 linker, and the a3-a4 linker to fill the void not
directly occupied by CC0651. The rearrangements in the imme-
diate vicinity of CC0651 occur with virtually no change in the
conformation of amino acid side chains and hence represent
almost perfect rigid body shifts (Figure S8A).
Mechanism of Action of CC0651
The structural alterations wrought by CC0651 could lead to
different possible mechanisms of catalytic interference. The
most pronounced rearrangement caused by CC0651 is the
wholesale shift in helix a2 that causes secondary conformational
changes in the active site region of hCdc34. The 310 helix that
bears the catalytic cysteine residue, which is buttressed against
the opposite surface of helix a2 to CC0651, is shifted 2.0 A˚ rela-
tive to the position observed in other apo-E2 structures such as
Ubc9 (Figure 5B). This movement causes a similar displacement
of the catalytic residues Tyr87 and Cys93, whereas the invariant
Asn85 of the HPN motif that participates in stabilization of the
oxyanion intermediate is shifted to a lesser degree. Notably, in
addition to its perturbation of the catalytic center, the binding
position of CC0651 on hCdc34 is proximal to a critical E2 surface
that noncovalently interacts with the thioester-linked donor ubiq-
uitin to facilitate catalysis (Figure 5C) (Hamilton et al., 2001; Saha
et al., 2011; Wickliffe et al., 2011). Finally, CC0651 also causes
a minor repositioning of helix a1, which comprises a portion of
the E1- and E3-binding sites that are conserved in all E2
enzymes (Figures S8B and S8C) (Huang et al., 2007; Zheng
et al., 2000). These various structural alterations could, in prin-
ciple, affect the E1-dependent charging reaction, the E2 catalytic
cycle, and/or the E3-mediated interactions with substrates.
To investigate whether E1 binding and the concomitant step of
E2ubiquitin thioester formation was adversely affected by
CC0651, we performed an E1-mediated ubiquitin charging
assay in the presence or absence of CC0651. The inhibitor had
little effect on formation of the hCdc34ubiquitin thioester, sug-
gesting that both E1 recognition and the initial catalytic charging
step were not perturbed (Figure 6A; see Figure S9A for reaction
kinetics). Two bioactive inhibitor analogs also did not affect the
levels of hCdc34 thioester formation in vivo (Figure 6B). We
then tested whether the interaction of hCdc34 with the SCFCdc4
E3 complex was affected by the inhibitor. Consistent with
previous results (Kleiger et al., 2009), hCdc34 could be captured
on an SCFCdc4 resin in a manner dependent on its acidic tail
region. The hCdc34-SCFCdc4 interaction was also not overtly
altered by CC0651, both in the presence and absence of Sic1
substrate (Figure 6C). The minor perturbations of the helix a1
region thus do not preclude the interaction of hCdc34 with either
E1 or E3 enzymes.
We then determined the effects of CC0651 on catalytic trans-
fer steps. CC0651 strongly impaired the rate of ubiquitin chain
initiation on substrate by SCFCdc4 (Figure 6D), as measured by
the monoubiquitination of Sic1 by K0 ubiquitin (Petroski and De-
shaies, 2003). In the absence of E3 and substrate, Cdc34 can
catalyze the formation of free polyubiquitin chains and also
autoubiquitinates itself to form a covalent monoubiquitinated
Cdc34 conjugate (Scaglione et al., 2007). Under these con-
ditions, CC0651 actually potentiated the formation of bothubiquitin dimers and monoubiquitinated hCdc34 (Figure 6E),
concordant with the observed accumulation of the hCdc34
conjugate in cells treated with the ester derivative of CC0651
(Figure 4E). Finally, as described previously (Seol et al., 1999),
purified human Cul1-Rbx1 complex stimulated the assembly of
extended polyubiquitin chains by hCdc34, as well as the forma-
tion of free di- and triubiquitin, and monoubiquitinated hCdc34
(Figure 6E). The addition of CC0651 to this reaction completely
inhibited the assembly of polyubiquitin chains and decreased
formation of free triubiquitin and, to a lesser extent, hCdc34
monoubiquitin, but had no effect on production of diubiquitin
(Figure 6E). The fact that Rbx1-Cul1 stimulated some hCdc34
activities, even at a concentration of inhibitor that abolished all
traces of substrate ubiquitination (Figure S5 and Figure S6),
was consistent with the fact that CC0651 did not appear to
inhibit the hCdc34-SCFCdc4 interaction. The selective effects of
CC0651 on the various hCdc34 reaction products suggested
that the inhibitor perturbs the ubiquitin transfer reaction in a
subtle and potentially substrate-selective fashion.
Given that hCdc34 and SCFCdc4 were able to interact in the
presence of CC0651, we reasoned that the CC0651-hCdc34
complex might exert a dominant-negative effect toward other
E2s that might otherwise catalyze SCF-mediated ubiquitination.
The closely related enzyme Ube2R2, which is completely resis-
tant to CC0651 (Figure 2D), fully supported Sic1 ubiquitination
even in the presence of excess Cys93Ala catalytic site and
Asn85Ala catalytic transfer mutants of hCdc34 (Figures 6F, 6G,
and 6H). However, in the presence of both hCdc34 and a high
concentration of CC0651, Sic1 ubiquitination by Ube2R2 was
potently inhibited (Figure 6F). Somewhat surprisingly, this domi-
nant-negative inhibitory activity of the CC0651-hCdc34 complex
did not depend on thioester formation or on catalytic transfer, as
shown by the equivalent dominant-negative effects of the cata-
lytic Cys and Asn mutants, respectively (Figure 6F–6H). The
dominant-negative effect was, however, greatly attenuated by
removal of the acidic tail of hCdc34 required for cullin interaction
or by mutation of hCdc34 residues required for CC0651 interac-
tion (Figures S10A–S10D). These results reveal a further unex-
pected feature of CC0651, which can evidently influence the
overall SCF ubiquitination reaction beyond its effects on the
catalytic transfer activity of hCdc34.
DISCUSSION
Our structural and biochemical analysis demonstrates that
CC0651 acts through an allosteric mechanism to inhibit ubiquitin
transfer to substrate, without overtly interfering with ubiquitin
thioester formation or essential interactions with E1 and E3
enzymes. Rather, our data suggest that CC0651 subverts the
catalytic activity of hCdc34 in a complex manner. Though the
inhibitor clearly abrogates the initial transfer of ubiquitin to
substrate and inhibits the autocatalytic assembly of longer ubiq-
uitin chains, it nevertheless stimulates hCdc34 autoubiquitination
and the formation of diubiquitin by free hCdc34. Thesedifferential
effects of CC0651 suggest that the underlying mechanics for
synthesis of each of these productsmay differ in subtle respects.
The dominant-negative effect of the CC0651-hCdc34 complex
may depend on the requirement for SCF dimer formation inCell 145, 1075–1087, June 24, 2011 ª2011 Elsevier Inc. 1083
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Figure 6. Mechanism of Action of CC0651
(A) Effect on hCdc34-ubiquitin thioester formation in vitro. hCdc34 was incubated with E1, ubiquitin, and ATP in the absence or presence of CC0651. Products
were resolved by SDS-PAGE in the presence or absence of DTT and were visualized by Coomassie blue.
(B) Effect on hCdc34-ubiquitin thioester formation in vivo. G0/G1-synchronized PC-3 cultures were treated with DMSO or CC0651, CC7094, and CC8993 (20 mM
each) or MLN4924 (4 mM) for 16 hr, and Cdc34 species in the presence or absence of DTT were detected by immunoblot.
(C) Effect on the hCdc34-SCFCdc4 interaction. SCFCdc4immobilized on resin was incubated with hCdc34 or hCdc34D tail in the presence or absence of CC0651
(100 mM) and E1, ubiquitin, and phospho-Sic1. hCdc34 retained after washing was detected by immunoblot.
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catalysis (Tang et al., 2007) and/or dimerization of hCdc34 itself
(Gazdoiu et al., 2007) but cannot be simply explainedby acatalyt-
ically inert complex because mutational inactivation of hCdc34
alone does not yield dominant-negative behavior. The fact that
this dominant-negative activity does not require the catalytic
ubiquitin thioester suggests that the inhibitor may form a nonco-
valent ternary complex with hCdc34 and ubiquitin that interferes
with the SCF catalytic cycle (Kleiger et al., 2009).
Recent evidence indicates that weak noncovalent interactions
of ubiquitin with different E2 surfaces are crucial for efficient
catalysis. A conserved interaction between the donor ubiquitin
and the E2 surface defined by contacts with helices a2, a3,
and a4 exposes the thioester linkage of the donor ubiquitin for
attack by the incoming acceptor ubiquitin during the chain elon-
gation reaction (Hamilton et al., 2001; Saha et al., 2011; Wickliffe
et al., 2011). In Ube2S, a second weak noncovalent interaction
surface helps to orient the acceptor ubiquitin for Lys11-specific
attack (Wickliffe et al., 2011), whereas in UbcH5, yet another
distinct ubiquitin contact surface (Figure S8D) appears to
mediate the assembly of polymers of the UbcH5-ubiquitin conju-
gate, whichmay be important for chain elongation (Brzovic et al.,
2006). These noncovalent ubiquitin interaction sites on Cdc34
may be perturbed upon inhibitor binding, although the donor
site is evidently not completely incapacitated because diubiqui-
tin conjugates can still form in the presence of inhibitor. This
observation contrasts with the effects of donor/acceptor site
mutations in Ube2S (Wickliffe et al., 2011) and catalytic aspara-
gine mutations (Wu et al., 2003), both of which potently abolish
diubiquitin synthesis. The further characterization of CC0651
mechanism of action, particularly the structure of CC0651 in
complex with hCdc34, ubiquitin, and SCF subunits, will shed
new light on the ubiquitin transfer reaction.
The specificity of CC0651 for hCdc34 over other E2 enzymes
is quite remarkable given the high degree of structural conserva-
tion and similarity of catalytic mechanism across the E2 family
(Wenzel et al., 2010). Our initial SAR analysis suggests that the
efficacy and bioavailability of CC0651 may be improved upon
by substitution of nonessential moieties. Our results also raise
the interesting possibility that analogous specific inhibitors
may be designed for other E2 enzymes. Indeed, inspection of
other known E2 structures reveals partially preformed pockets
in the vicinity of the CC0651-binding region (see Figure S11). It
is conceivable that the CC0651 pocket represents a general
allosteric control site that may respond to physiological ligands
that regulate E2 activity (Nakada et al., 2010).
The UPS hierarchy is, in principle, susceptible to inhibition at
each of its different levels of specificity. To date, only the general
26S proteasome inhibitor bortezomib has been approved for use
against human cancer (Nalepa et al., 2006). Intensive efforts are
now underway to identify inhibitors of other UPS enzymes
(Cohen and Tcherpakov, 2010). With respect to the CRLs, inhibi-(D) Effect on conjugation of initial ubiquitin. Monoubiquitination of phospho-Sic1 w
of CC0651.
(E) Effect on hCdc34 reaction product distribution. The indicated reactions were
(F, G, and H) Dominant interference with Ube2R2-mediated ubiquitination. Phosph
wild-type or mutant forms of hCdc34 were incubated in the presence or absenc
See Figure S9 and Figure S10 for associated data.tion of cullin neddylation by MLN4924 also shows promise in
preclinical cancer models (Soucy et al., 2009). Due to the partial
redundancy of CRL-associated E2s, the inhibition of hCdc34
may afford similar, if not greater, specificity than inhibition of
CRL neddylation. In terms of potential clinical indications for
hCdc34, the enzyme is highly expressed in T cell acute lympho-
blastic leukemia (Eliseeva et al., 2001), and a dominant-negative
allele of hCdc34 enhances the efficacy of bortezomib against
multiple myeloma (Chauhan et al., 2004). Recently, hCdc34 has
emerged as a critical target of the let-7microRNA (Legesse-Miller
et al., 2009), which is a tumor suppressor (Bu¨ssing et al., 2008).
The development of inhibitors that act at each enzymatic step
of SCF-dependent catalysis, including inhibitors of specific
F box proteins (Aghajan et al., 2010; Orlicky et al., 2010), should
allow the eventual implementation of highly specific combi-
natorial therapeutics. Our discovery and characterization of
CC0651 demonstrates that the E2 enzymatic step in the ubiquiti-
nation cascade is specifically susceptible to small-molecule
intervention.EXPERIMENTAL PROCEDURES
Recombinant Protein Production
E1, hCdc34, and human Cks1 were expressed in E. coli and purified by affinity
tags and size exclusion chromatography. The SCFSkp2 complex was affinity
purified from Sf9 cells co-infected with recombinant baculoviruses that
expressed GST-Skp2, His-Skp1, His-Cul1, and Rbx1. SCFFbw7, SCFbTrCP,
p27-Cdk2-cyclin E, FLAGp27-Cdk2-cyclin E, FLAGp27T187A-Cdk2-cyclin E, and
Cdk2-cyclin E complexes were also affinity purified from Sf9 cells co-infected
with recombinant baculoviruses. Ubiquitin was labeled with EZ-link Sulfo-
NHS-LC-biotin. Phospho-p27Kip1 was prepared by incubating 0.1 mg/ml
Cdk2-cyclin E (1.25 mM) with 0.1 mg/ml (1 mM) p27-Cdk2-cyclin E
or FLAGp27-Cdk2-cyclin E at 23C for 2 hr in kinase buffer (40 mM Tris-HCl
[pH7.5], 10 mM MgCl2, 1 mM DTT, and 1 mM ATP). Protein aggregation was
assessed by light scattering analysis in the presence or absence of 1 mM
CC0651 and 0.4 mg/ml protein.
SCF Ubiquitination and Interaction Assays
For small-molecule screens, p27Kip1 was ubiquitinated in a 15 ml reaction with
40 nM phospho-p27, 40 nM E1, 5 mM E2, 25 nM SCFSkp2, 25 nM Cks1, and
27.8 mM biotinylated ubiquitin in 40 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 1 mM
DTT, and 0.5 mM ATP at 23C for 3 hr. The reaction was terminated with assay
diluent (BD PharMingen), transferred to 384-well protein A plates (Pierce Tech-
nology) coatedwith 62 ng SC528 antibody (Santa Cruz), incubated for 1 hr, and
washed six times with 10 mM Tris-HCl [pH 7.6], 0.05% Tween20 prior to addi-
tion of 25 ml of 0.4 mg/ml europium streptavidin in HEPES [pH 7.6], 1% BSA,
0.2% Tween20 per well. Plates were incubated for 1 hr, washed, and read for
Eu-time-resolved fluorescence after addition of 25 ml enhancement solution
(Perkin Elmer). For gel-based ubiquitination assays, CC0651 and its analogs
were preincubated at the indicated concentrations with 0.5 mg E1, 1–4 mg
hCdc34, and 50 ng SCFCdc4, 100 ng SCFFbw7, 150 ng SCFbTrCP, or 50 ng
SCFSkp2 for 10–45 min at 4C in 20 ml reaction buffer (50 mM HEPES [pH 7.5],
10mMMgCl2, 2mMATP, and 50 mMDTT). Reactionswere initiated by addition
of 1 mg ubiquitin and respective SCF substrates (50 ng HisSic1 phosphorylated
byCln2-Cdc28, 50ng cyclin E phosphorylated byCdk2, 25 ng biotinylated IkBaith K0-ubiquitin was assessed in the presence of the indicated concentrations
visualized by antiubiquitin immunoblot.
o-Sic1 ubiquitination reactions with the indicated amounts (mg) of Ube2R2 and
e of 100 mM CC0651 and were visualized by anti-Sic1 immunoblot.
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phosphopeptide [KKERLLDDHDpSGLDpSMKDEE], or 50 ng p27Kip1 phos-
phorylated by cyclin E-Cdk2), incubated at 30C for 1–3 hr, and products visu-
alized by immunoblot (Tang et al., 2007). For E2 charging reactions, 0.1 mg E1,
5 mg hCdc34, 25 mg ubiquitin, and indicated amounts of CC0651 were preincu-
bated for 15minat 23C in25ml reactionbuffer (50mMHEPES [pH7.5], 100mM
NaCl) and then initiated with 2 mM ATP at 30C, terminated by loading buffer
with or without 5 mM DTT, and visualized by SDS-PAGE and Coomassie
blue. For the Cdc34-SCFCdc4 interaction, 250 ng of SCFCdc4-FLAG or FLAG-
Skp1 immobilized on anti-FLAG M2 resin (Sigma) was incubated with 4 mg of
His-Cdc34 or Cdc34Dtail in the presence or absence of 100 mM CC0651,
50 ng phospho-Sic1 substrate, and/or 0.5 mg E1, washed, and visualized by
anti-Cdc34 immunoblot.
Cell Culture Analysis
PC-3 and HCT116 cell lines were grown in DMEM supplemented with
penicillin/streptomycin, 2 mM glutamine, and 10% fetal bovine serum (FBS).
Lentiviral shRNA constructs (Sigma) for human CDC34 (TRCN0000007300
[sh2] and TRCN0000007302 [sh4]), UBE2R2 (TRCN0000004227 [sh1] and
TRCN0000004229 [sh2]), and nontarget control were used as described
(Voisin et al., 2008). For proliferation assays, PC-3 cultures were seeded at
5000 cells/well in quadruplicate in 24-well plates, grown for 24 hr, and then
infected with lentiviral supernatant. For small-molecule inhibition, cells were
seeded in quadruplicate at 500 cells/well in 96-well plates, grown for 24 hr,
and treated with compound. Proliferation was measured by MTT assay (Voisin
et al., 2008). PC-3 or HCT 116 cultures were synchronized in G0/G1 by serum
starvation for 30 hr and then released by addition of 10% serum. For epistasis
experiments, PC-3 cells were infected with CDC34 shRNA for 24 hr, followed
by addition of inhibitor and assessment of proliferation after 4 days. Anti-
Cdc34 (17/CDC34BD Transduction Laboratories), anti-p27 (610242 BD Trans-
duction Laboratories), anti-a-tubulin (DM1A Sigma), anti-ubiquitin (MMS-257P
Covance), and anti-cyclin E (Wang et al., 1999) antibodies were used as
described (Servant et al., 2000).
X-Ray Structure Determination
Crystals of apo-hCdc34D184 at 42 mg/ml in 20 mM Tris-HCl (pH 8.0), 0.15 M
NaCl, 5% glycerol, and 2 mM DTT were grown in hanging drops by mixing
2 ml protein solution with 2 ml well solution (28% PEG 4000, 0.1 M Tris-HCl,
pH 8.5, 0.2 M MgCl2, 1 mM DTT, and 7.5 mM glycyl-glycyl-glycine) at 21
C.
Crystals of the CC0651-hCdc34D184 complex were grown in well solution
containing 100 mM imidazole (pH 8.0), 200 mM NaCl, 0.5 M NaH2PO4,
and 1.6 M K2HPO4. For cryoprotection, crystals were soaked in well solution
supplemented with 25% ethylene glycol. Diffraction data sets were
collected at IMCA-CAT 17-ID-B and NE-CAT 24-ID-E (APS, Chicago, IL),
respectively, and processed with HKL2000 (Otwinowski and Minor, 1997).
Molecular replacement was performed using MolRep (Vagin and Teplyakov,
2010) using the crystal structure of UbcH7 (PDB: 1FBV) or apo hCdc34 as a
search model (Zheng et al., 2000). Atomic models were rebuilt using COOT
(Emsley and Cowtan, 2004) and refined using Refmac (Murshudov et al.,
1997).
ACCESSION NUMBERS
The Cdc34 and Cdc34-CC0651 complex structures have been deposited in
the Protein Data Bank under ID codes 2ob4 and 3rz3, respectively.
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